Tashkent, Uzbekistan (UzDaily.com) -- Global biopharmaceutical company Takeda has announced the appointment of Ebru Yavuz as CEO of the newly formed Ukraine and CIS cluster. The announcement follows a recent organizational update regarding Takeda’s core clusters, i.e. Ukraine, Belarus, Moldova, Asia and the Caucasus cluster. 

Thus, this merger forms the Cluster of Ukraine and the CIS (Commonwealth of Independent States), which includes: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Uzbekistan and Ukraine.

Ebru Yavuz has over 20 years of experience and extensive operational knowledge in the pharmaceutical industry, industry regulatory and senior strategic leadership experience. Ebru Yavuz joined Takeda in February 2016 as Head of Business Operations at Takeda Pharmaceuticals for ICMEA (India, CIS, Middle East, Turkey and Africa), developing a business strategy to grow, improve and optimize the company. business operations. Her rich experience and understanding of industry dynamics will help drive sustainable growth in Takeda’s key markets.

Commenting on her appointment, Ebru Yavuz said: “I am very excited about Takeda’s ongoing development in the Ukrainian and CIS markets and look forward to working with the team and our partners to ensure and meet the growing needs of our patients with innovative therapies. Our partnerships with national health systems for a variety of diseases ensure greater access and overall patient well-being, while ensuring sustainable growth. Guided by our values, we continue to strive to ensure a bright future for people across the entire cluster of Ukraine and the CIS. As we strive to reduce complexity and deliver greater economies of scale through our new structure, our people and the needs of our patients will always remain our top priority.”

The newly formed Ukraine and CIS Cluster is part of the ICMEA region, where Takeda’s innovative medicines are available to approximately 3.3 billion people, or 40% of the world’s population. Takeda’s activities in the Republic of Kazakhstan are focused on the rapid, sustainable and affordable advancement of innovative treatments to existing and future patients in key areas of therapy. Today, in Kazakhstan, Takeda occupies 3% of the pharmaceutical market, being in 6th place.